After surgery, PSA should become “undetectable” on a normal PSA test (i.e., < 0.1 ng/ml) within a month or two, but sometimes it remains elevated. The primary purpose of the ARO 96-02 randomized clinical trial was to determine whether there was an advantage to treating stage T3-4N0 patients while PSA was still undetectable, or whether […]![]()
